Blinatumomab Improves Survival in B-Lineage ALL Patients Froelich, Warren Froelich, Warren Less Oncology Times. 45(S4):1,3, February 20, 2023. Favorite PDF Permissions Free
Low-Dose Dasatinib as Frontline Therapy in CML Nalley, Catlin Nalley, Catlin Less Oncology Times. 45(S4):1,4, February 20, 2023. Favorite PDF Permissions Free
Immediate Progression to Stem Cell Transplant Possible for R/R AML Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 45(S4):5, February 20, 2023. Favorite PDF Permissions Free
Bispecific Antibody Therapy in Heavily Pretreated Multiple Myeloma Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 45(S4):6, February 20, 2023. Favorite PDF Permissions Free
Ibrutinib & Venetoclax Superior to Clb+O for CLL in GLOW Study Holt, Chuck Holt, Chuck Less Oncology Times. 45(S4):7, February 20, 2023. Favorite PDF Permissions Free
Novel Drug Activates NK Cells for Treatment of AML, ALL, & MDS DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 45(S4):8, February 20, 2023. Favorite PDF Permissions Free
Azacitidine With Venetoclax & Magrolimab for Acute Myeloid Leukemia Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 45(S4):9, February 20, 2023. Favorite PDF Permissions Free
Ibrutinib May Replace Stem Cell Transplantation for MCL Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 45(S4):10, February 20, 2023. Favorite PDF Permissions Free
Restrictive Diet Causes Unnecessary Burden After Stem Cell Transplant Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 45(S4):11, February 20, 2023. Favorite PDF Permissions Free
Hodgkin Lymphoma Survivors May Have Epigenetic Accelerated Aging Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 45(S4):12, February 20, 2023. Favorite PDF Permissions Free
National Data System on Blood Transfusions to Save Lives & Money Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 45(S4):13, February 20, 2023. Favorite PDF Permissions Free
Underrepresented Groups Often Excluded From Lymphoma Clinical Trials Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 45(S4):14, February 20, 2023. Favorite PDF Permissions Free
Social Determinants of Health Affect Pulmonary Embolism Treatment Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 45(S4):15, February 20, 2023. Favorite PDF Permissions Free
Global Utilization of Hematopoietic Stem Cell Transplantation for AML Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 45(S4):16, February 20, 2023. Favorite PDF Permissions Free
High-Dose Methotrexate Fails to Reduce CNS Relapse in Young ALL Patients Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 45(S4):17, February 20, 2023. Favorite PDF Permissions Free
Socially Vulnerable Patients Receive More Specialized Stem Cell Transplants Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 45(S4):18, February 20, 2023. Favorite PDF Permissions Free
Initiative Identifies Racial Disparities in Multiple Myeloma Care Nalley, Catlin Nalley, Catlin Less Oncology Times. 45(S4):19, February 20, 2023. Favorite PDF Permissions Free
Strategies for Implementing an Oral Medication Adherence Intervention Nalley, Catlin Nalley, Catlin Less Oncology Times. 45(S4):20, February 20, 2023. Favorite PDF Permissions Free
Predicting CAR-T Outcomes in Patients With DLBCL Nalley, Catlin Nalley, Catlin Less Oncology Times. 45(S4):21, February 20, 2023. Favorite PDF Permissions Free
Formula-Fed Preterm Infants More Likely to Have Iron Deficiency Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 45(S4):22, February 20, 2023. Favorite PDF Permissions Free
FDA Updates Highlighting the Latest Cancer Treatments Less Oncology Times. 45(S4):23, February 20, 2023. Favorite PDF Permissions Free
